The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC ...

Merck (MRK) stock is in focus as the FDA approves a label expansion for the company's kidney cancer drug Welireg with its ...

Regulatory clearance includes IV pembrolizumab and subcutaneous pembrolizumab/berahyaluronidase with belzutifan for adjuvant treatment after nephrectomy, including ...

The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is ...

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...